Categories: News

CBD of Denver Achieves 26% Revenue Growth and Returns to Positive Operating Income in 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Denver, Colorado–(Newsfile Corp. – March 31, 2025) – CBD of Denver, Inc. (OTC Pink: CBDD), a diversified holding company, today announced key financial highlights for the fiscal year ended December 31, 2024, demonstrating strong revenue growth and a return to positive operating income.

2024 Highlights:

Revenue grew to $3.75 million, a 26% increase compared to $2.98 million in 2023, driven by consistent performance from the Company’s wholesale CBD division.

Operating income turned positive, improving by more than $338,000 year-over-year.

Operating expenses were reduced by 58%, reflecting a more efficient, focused organization.

No new convertible debt was issued during the year, maintaining a cleaner capital structure.

Shareholders’ equity improved, further stabilizing the balance sheet.

“We’re proud of the progress we made in 2024,” said Jan Schwager, CEO of CBD of Denver. “With strong top-line growth and significant cost savings, we’ve created a leaner, more agile company that is now well-positioned to pursue new opportunities in tech-driven sectors.”

The Company remains focused on expanding its revenue base, maintaining financial discipline, and creating long-term shareholder value.

New Strategic Alignment

CBD of Denver is repositioning itself as a dynamic holding company focused on incubating and accelerating a broad range of innovative businesses, with an emphasis on the tech sector. Building on its operational and financial turnaround, the company will explore opportunities across digital payments, blockchain, AI, and other scalable technology-driven solutions. This strategic shift reflects CBD of Denver’s long-term vision to create a diversified portfolio of forward-thinking ventures that can deliver sustainable value to shareholders.

About CBD of Denver, Inc.

CBD of Denver, Inc. is focused on acquiring profitable assets at attractive valuations to create value for shareholders. The company’s team is dedicated to sourcing high-margin, innovative products that align with its values.

For inquiries, please contact Investor Relations: info@cbdofdenverinc.com.

Follow Us: Twitter

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246723

Staff

Recent Posts

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

2 hours ago

Lam Research Corporation Announces March Quarter Financial Conference Call

FREMONT, Calif., April 2, 2025 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

4 hours ago

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development,…

4 hours ago

Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billionExpands Siemens' market-leading…

4 hours ago

PerZeption Appoints CTO to Enhance Visual Function Assessments

BOSTON, April 2, 2025 /PRNewswire/ -- PerZeption Inc., a U.S. vision diagnostics startup dedicated to…

4 hours ago

Dotmatics Signs Definitive Agreement to be Acquired by Siemens Advancing a New Era of AI-Driven Innovation in Life Sciences

Siemens AG will acquire Dotmatics from global software investor Insight Partners for $5.1 billionAcquisition accelerates…

4 hours ago